

1

2

3 **Enhanced Golic+: Gene targeting with 100% recovery in**

4 ***Drosophila* male germ cells**

5

6

7 Hui-Min Chen, Xiaohao Yao, Qingzhong Ren, Chuan-Chie Chang, Ling-Yu Liu, Tzumin

8 Lee*

9

10

11 Howard Hughes Medical Institute, Janelia Research Campus, 19700 Helix Drive,

12 Ashburn, VA 20147, USA

13

14

15 * To whom correspondence should be addressed.

16 Tel: 571-209-4198

17 Email: leet@janelia.hhmi.org

18 **ABSTRACT**

19

20 The efficiency of gene targeting can vary drastically. Even utilizing CRISPR/Cas9
21 does not ensure rapid, successful gene targeting. In *Drosophila*, we previously
22 established Golic+ to augment gene-targeting productivity simply through fly
23 pushing. This transgene-based system elicits gene targeting in germ cells. It further
24 implements lethality selection to enrich for progeny with accurate gene targeting.
25 However, limitations still remain. Here we deliver an improved Golic+ technique
26 that we name Enhanced Golic+ (E-Golic+). E-Golic+ incorporates genetic
27 modifications to eliminate false positives while simultaneously boosting efficiency.
28 Strikingly, male germ cells are exceptionally susceptible to gene targeting using E-
29 Golic+. With male founders, we easily achieve 100% recovery of correct gene
30 targeting. Given the superior efficiency/specificity and relatively effortless
31 scalability, E-Golic+ promises to triumph in any challenging and otherwise
32 unattainable gene targeting projects in *Drosophila*.

33

34

35 **KEY WORDS: *Drosophila*, Gene targeting, Homologous recombination, CRISPR,**
36 **Male germline, Lethality-based selection**

37

38

39 **INTRODUCTION**

40

41 The prokaryotic immune system, CRISPR/Cas9, has been successfully adopted for
42 genome editing in diverse species (Komor et al. 2017). An engineered, widely used
43 CRISPR/Cas9 system consists of two components: a single-molecule guide RNA
44 (gRNA) and the Cas9 DNA endonuclease (Jinek et al. 2012; Hwang et al. 2013). The
45 gRNA binds with Cas9 and directs Cas9 to produce double-strand DNA breaks in
46 specific DNA sequences determined by base pairing between the gRNA and a 20bp
47 DNA target. The only additional requirement in the DNA is the presence of
48 protospacer adjacent motif (PAM, canonically NGG) immediately following the 20bp
49 target sequence. One can therefore utilize CRISPR/Cas9 to target almost any
50 genomic region with extremely high selectivity. The resultant DNA breaks are often
51 repaired by non-homologous end joining (Lieber 2010), leading to deletions or (less
52 frequently) insertions until the target sequence is lost. Notably, the likely indel
53 profiles can be largely predicted based on local DNA sequences (Allen et al. 2018).
54 The simplicity, robustness and predictability of Cas9-induced indels have made
55 CRISPR as the most favored strategy for targeted gene disruption. Further, one can
56 try to edit the genome around the Cas9 cut site via homology directed repair (HDR)
57 of DNA breaks (San Filippo et al. 2008). With HDR, one can replace endogenous
58 sequences with some designer sequences by supplying an exogenous template
59 carrying the desired DNA sequence flanked by homology arms. Such tailored
60 genome modifications are versatile but can be difficult if not impossible to achieve
61 even with the CRISPR technology (Horlbeck et al. 2016; Isaac et al. 2016).
62

63 Gene targeting is context-dependent and offers little flexibility in the design. Some
64 gene-targeting experiments are intrinsically more challenging than others. For
65 instance, certain manipulations strive for deletion of a sizable defined DNA fragment
66 or insertion of a long DNA sequence at a specific nucleotide position. This can be
67 extremely challenging if suitable gRNA sites are not available. Moreover, it can be
68 difficult to obtain and insert long homology arms into an already lengthy donor
69 DNA. In addition, the engineered gene products (made through correct gene
70 targeting) may unexpectedly compromise organism viability even in heterozygous
71 conditions. To recover rare gene-targeting events in those challenging cases
72 requires (1) generation of numerous offspring, each with independent trials, and (2)
73 enrichment of offspring with correct gene targeting (especially those with decreased
74 viability) by selection against ‘unperturbed’ progeny.

75

76 Golic+ is a transgene-based gene targeting system designed to achieve the above
77 two objectives (Chen et al. 2015). First, it employs a *bam* promoter to confine gene
78 targeting to germ cells rather than germline stem cells (Chen and McKearin 2003;
79 Lehmann 2012). This theoretically guarantees independent gene targeting events in
80 individual offspring. Second, it carries two conditional toxic genes: one to eliminate
81 offspring that did not incorporate the donor DNA and the other to select against the
82 incorporation of donor DNA in off-target sites. These lethality-based selections
83 should therefore allow only offspring with correct gene targeting to survive into
84 adults. We envisioned that a low probability gene-targeting event would occur
85 eventually, and that assuming no recovery of false positives in Golic+, patience and

86 simple fly pushing would be all that is needed to ensure success. The induction of
87 gene targeting in germ cells further eliminates the need for single-founder crosses, a
88 practice to avoid recovery of clonally identical lines. The amount of fly pushing can
89 therefore be greatly reduced. Thus, for complex editing of genes in their native
90 environment, Golic+ is particularly affordable compared to embryo injections.

91

92 Nonetheless, since its debut in 2015, the original Golic+ failed to succeed at all gene-
93 targeting experiments. We suspended several trials due to the inability to recover
94 correct gene targeting events after proving many candidates as false positives. In
95 this study, we deliver an enhanced Golic+ (E-Golic+) with (1) much more stringent
96 lethality selections plus (2) superior gene targeting efficiency. Strikingly, the E-
97 Golic+ acts much more potently in male than female germ cells. From male founders,
98 we easily achieve a 100% success-rate with previously failed gene-targeting
99 experiments. Only in the most challenging case did we detect any false positives. In
100 this case, offspring with off-target integration were outnumbered two-fold by
101 offspring with correct gene targeting. Therefore, for extremely intractable or large-
102 scale gene targeting experiments, one can perform group crosses to drastically
103 reduce the labor required for making numerous independent trials with minimal
104 false-positive contamination. In conclusion, E-Golic+ guarantees successful gene
105 targeting in *Drosophila*.

106

107

108 **RESULTS**

109

110 **Enhanced Golic+ reduces false positives while boosting efficiency**


111

112 With Golic+, we can readily expand fly crosses to increase independent gene-
113 targeting trials. However, despite lethality-based selections, most gene targeting
114 trials yielded a significant number of false positives; and some Golic+ crosses
115 produced very few survivors in total. We therefore re-examined the Golic+ design
116 for potential shortcomings. In Golic+, a minimal *bam* promoter, *bamP(198)* co-
117 expresses Cas9, FLP, and I-SceI in female germ cells. Cas9 directed by gRNA makes
118 specific DNA cuts in the target gene. FLP mediates formation of the circular donor
119 DNA from a pre-integrated FRT cassette, and I-SceI subsequently linearizes the
120 donor. Golic+ further employs three LexA-dependent transgenes, including one
121 repressible and one non-repressible toxic gene as well as a repressor gene, for
122 lethality-based progeny selection. The repressible toxic gene exists in two parts
123 separated by an FRT cassette that contains 5' homology arm, the repressor gene, 3'
124 homology arm, and the non-repressible toxic gene in sequence. Excision of the FRT
125 cassette would automatically reconstitute the repressible toxic gene at the original
126 integration site of the donor DNA. We can then render organism survival contingent
127 upon re-integration of the repressor gene. However, the liberated donor DNA
128 carries the repressor gene as well as a non-repressible toxic gene. Given only the
129 repressor gene flanked by homology arms, HDR-mediated gene targeting would
130 naturally segregate the repressor gene from the non-repressible toxic gene and

131 selectively place the repressor gene back to the genome. Thus, Golic+ permits
132 enrichment of correct gene targeting.
133
134 Given the dependence of all key enzymes on the *bam* promoter, we first wondered if
135 the strength of bamP(198) is a key limiting factor in the performance of Golic+. We
136 addressed this issue by trying bamP(898), a longer and presumably stronger *bam*
137 promoter (Chen and McKearin 2003). Notably, co-induction of Cas9, FLP, and I-SceI
138 by bamP(898) yielded many more survivors including false positives at even higher
139 ratios (Supplemental Table). The predominance of false positives overshadowed the
140 evidently more potent bamP(898). To improve the efficiency of Golic+ we need to
141 further identify and eliminate the source(s) of false positives.

142
143 We detected two categories of false positives. The first group consisted of escapers,
144 those without donor DNA incorporation. Errors in the donor DNA liberation step
145 resulted in defective reconstitution of the repressible toxicity gene (Fig. 1A).
146 Without a functional repressible toxic module, organism viability was no longer
147 coupled to genome incorporation of the donor DNA. To eliminate these escapers, we
148 need to ensure presence of an intact, repressible toxic gene ideally at the same
149 homologous site as the pre-integrated donor DNA. We met this requirement by
150 making and placing the 3xP3-RFP-marked *3XLexAop2-riTS-Rac^{V12}* transgene at the
151 same *attP* sites used for holding donor DNAs (Fig. 1B). This guarantees that all
152 3xP3-RFP-marked survivors carry an intact repressible toxic gene. Organism

153



154

155 **Figure 1. Improvements of E-Golic+ to remove two types of false positives,**
 156 **escapers and non-specific insertions.** (A) In Golic+, {donor} was designed with
 157 two built-in toxicity modules and integrated in pre-characterized *attP* sites for
 158 efficient donor DNA release. We detected two false positive scenarios that produced
 159 progeny evading lethality selection. For escapers, they originated from failures in
 160 the reconstitution of a toxic module at the {donor} residual site, due to either
 161 imprecise flip-out or destructive premature I-SceI cutting. Therefore, they eclosed
 162 without ever being challenged by the lethality selection. For non-specific insertions,
 163 they retained the rCD2i suppressor and primarily relocated into the same
 164 chromosome. Yet they lost the ancillary non-repressible toxic module over this
 165 process, and survived the lethality selection without going through HDR. (B) We
 166 created 3xP3-RFP labeled *3XLexAop2-riTS-Rac1^{V12}* transgenic lines, and
 167 purposefully only collected surviving candidates marked with red fluorescent eyes.
 168 Hence, we effectively screened for candidates carrying the rCD2i suppressor, and
 169 avoid escapers completely. (C) Using *bamP(898)-Cas9:T2A:FLP*, we induced HDR in
 170 germ cells with CRISPR and circular donor DNA, hence directly relieved ourselves
 171 from the occurrence of non-specific insertions originating from linear donor DNA.
 172

173

174 survival would therefore depend on relocation of the repressor-marked donor DNA
175 onto a different (hopefully the desired) chromosome.

176

177 The second group of false positives resulted from non-specific insertions of the
178 donor DNA. Per Golic+ design, HDR at the correct target site should segregate the
179 repressor and the non-repressible toxic gene, as they are separated by one of the
180 paired homology arms. By contrast, organisms with non-specific insertions should
181 retain the non-repressible toxic gene and fail to survive upon selection with some
182 broad LexA driver. However, the non-specific insertions we recovered had
183 somehow selectively lost the non-repressible toxic gene (Fig. 1A). While we do not
184 know how this occurred, we may be able to better preserve the integrity of the
185 liberated donor DNA by keeping it in a circular form. Further, linear DNA can
186 promote non-specific insertion and circular DNA is competent as a template for HDR
187 (Beumer et al. 2008). To this end, we made *bamP(898)-Cas9:T2A:FLP* that drives
188 only Cas9 and FLP, thus excluding I-SceI (Fig. 1C). We refer to Golic+ with
189 *bamP(898)-Cas9:T2A:FLP* plus 3xP3-RFP-marked *3XLexAop2-riTS-Rac^{V12}* as
190 Enhanced Golic+. Please see Table 1 for transgenes required for implementing
191 enhanced Golic+ and Figure 2 for representative targeting schemes.

192

193 We performed a direct comparison of Golic+ with E-Golic+ to see if we could
194 eliminate false positives and increase efficiency. Using enhanced Golic+, we
195 effectively eliminated all false positives observed in three previously failed Golic+
196 experiments (Fig. 3). We were further able to recover multiple correct gene-

197 **Table 1. List of transgenic lines required for implementing Enhanced Golic+**
198

Full Name	Abbreviation	Integration Site(s)	Notes
donor DNA plus gRNA in pTL2	{donor, gRNA}	attP40, VK00027	Needs to be created for each gene-targeting experiment.
GMR3-LexA::GADd	GMR3-LexA	attP40, VK00027	Cross with {donor, gRNA} injected adults to create rough eyes for {donor} transformant screening.
bamP(898)-Cas9-P2A-FLP	bam898-CF	su(Hw)attP8, attP2	Expresses Cas9 and FLP under bamP control to introduce DSB at the target locus and release donor DNA in every germ cell.
3XLexAop2-rCD2miRNATS#6-Rac1 ^{V12} (3xP3-RFP)	3X-riTS-Rac1 ^{V12}	attP40, VK00027	Together with {donor, gRNA} [*] , provides a homozygous suppressible “Toxic” background.
Residual {donor, gRNA}	{donor, gRNA} [*]		After donor release, it will reconstitute as a suppressible toxic module, 5X-FRT-riTS-Rac1 ^{V12} .
nSyb-LexA::p65	nSyb-LexA	attP16, VK00027	Induce larval/pupal lethality selection

199

Targeting 2nd Chromosome

Targeting X Chromosome

Donor Release & Targeting $\{donor, gRNA\}$ in VK27 \times $bam898-CF$ in $su(Hw)attP8$; $3X-riTS-RacI^{V12}$. $3xP3-RFP$ in VK27 $\{donor, gRNA\}$ in $attP40$ \times $3X-riTS-RacI^{V12}$. $3xP3-RFP$ in $attP40$; $bam898-CF$ in $attP2$


Lethality Selection $\frac{Pin}{CyO}$; $nSyb-LexA$ in VK27 \times $\frac{bam898-CF}{+}$; $\frac{gene-X^*}{+}$; $\frac{\{donor, gRNA\}^*}{3X-riTS-RacI^{V12}}$ $\frac{nSyb-LexA}{+}$ in $attP16$ \times $\frac{gene-X^*}{+}$; $\frac{\{donor, gRNA\}^*}{3X-riTS-RacI^{V12}}$; $\frac{bam898-CF}{+}$

Candidate Collection $\frac{bam898-CF / +}{Y / +}$; $\frac{gene-X^*}{Pin / CyO}$; $\frac{3X-riTS-RacI^{V12}}{nSyb-LexA}$ $\frac{gene-X^*}{Y / +}$; $\frac{3X-riTS-RacI^{V12}}{nSyb-LexA}$; $\frac{bam898-CF / +}{+}$

200
201
202
203
204
205

Figure 2. Targeting schemes for a second or an X chromosome gene. Like Golic+, E-Golic+ involves two crosses and three steps. In the first cross, we create founders that have active CRISPR reactions with circular donor for HDR in their germ cells. Then, founders are mated with *nSyb-LexA* so that each progeny will experience lethality selection, and most, if not all, of the 3xP3-RFP marked surviving candidates inherit gene targeting events marked with rCD2i suppressor.

206



207

208

209

210

211

212

213

214

215

Figure 3. E-Golic+ effectively eliminates the occurrence of false positives. To evaluate the new transgenes introduced in E-Golic+, we performed gene targeting with five different donors using either Golic+ or E-Golic+. Occurrence of three different types of gene targeting candidates (correct targeting, non-specific insertion, and escapers) out of every 100 female founders are numbers interpolated or extrapolated from data in Table 2.

216 targeting events in one of the three genes we tested. These results substantiate the
217 success in eliminating false positives with the newly introduced transgenes plus use
218 of circular templates instead. However, two of the three repeated trials remained
219 unsuccessful, demanding larger scales of fly pushing or higher gene targeting
220 efficiencies.

221

222 **Males make superior founders**

223

224 One laborious step of performing E-Golic+ is the collection of copious virgin females
225 to be founders. Conversely, using males as founders would significantly reduce the
226 load of fly pushing when many founders are needed to obtain rare gene targeting
227 events. Males should be able to be used as founders as *bam* shows comparable
228 restricted expression in both male and female gonads (Fuller and Spradling 2007).
229 Hence, use of *bamP898* in E-Golic+ should also effectively confine gene targeting to
230 male germ cells. We therefore repeated all three gene-targeting experiments with E-
231 Golic+ in male founders.

232


233 Using male founders, we readily recovered numerous correct gene-targeting
234 offspring from each of the three gene-targeting trials (Table 2). None of these trials
235 were successful with Golic+, and only one was successful with E-Golic+ using female
236 founders. To make *vnd:T2A:KD*, we recovered 73 offspring with *vnd:T2A:KD* from a
237 total of 200 male founders, as opposed to only 17 from a total of 300 female
238 founders. In the engineering of *Nkx6:T2A:DBD*, we utilized two gRNA choices and

239 **Table 2. Comparison of Golic+ and Enhanced Golic+**

	# of Founders	Correct Targeting	Non-Specific Insertion	Escapers
Golic+	Female			
{ <i>vnd-T2A-KD, gRNA#1</i> }	100	0	17	47
{ <i>vnd-T2A-KD, gRNA#2</i> }	100	0	28	49
E-Golic+	Female			
{ <i>vnd-T2A-KD, gRNA#1</i> }	150	4	0	0
{ <i>vnd-T2A-KD, gRNA#2</i> }	150	13	0	0
E-Golic+	Male			
{ <i>vnd-T2A-KD, gRNA#1</i> }	100	49	0	0
{ <i>vnd-T2A-KD, gRNA#2</i> }	100	24	0	0
Golic+	Female			
{ <i>Nkx6-T2A-DBD, gRNA#1</i> }	50	0	29	39
{ <i>Nkx6-T2A-DBD, gRNA#2</i> }	50	0	24	23
E-Golic+	Female			
{ <i>Nkx6-T2A-DBD, gRNA#1</i> }	65	0	0	0
{ <i>Nkx6-T2A-DBD, gRNA#2</i> }	120	0	0	0
E-Golic+	Male			
{ <i>Nkx6-T2A-DBD, gRNA#1</i> }	75	16	0	0
{ <i>Nkx6-T2A-DBD, gRNA#2</i> }	100	21	0	0
Golic+	Female			
{ <i>Gad1-T2A-Gal4, gRNA#1</i> }	350	0	12	56
E-Golic+	Female			
{ <i>Gad1-T2A-Gal4, gRNA#1</i> }	100	0	0	0
E-Golic+	Male			
{ <i>Gad1-T2A-Gal4, gRNA#1</i> }	300	6	3	0

240 To examine the improvements made on E-Golic+, both Golic+ and E-Golic+ were
241 applied to create *vnd-T2A-KD*, *Nkx6-T2A-DBD*, and *Gad1-T2A-Gal4* knock-ins. In the
242 last *Gad1-T2A-Gal4* knock-in case, we only construct one {donor, gRNA} for
243 targeting. Female founders were used in both Golic+ and E-Golic+ to reveal the
244 benefits of adopting circular donor plus a 3xP3-RFP marked 3X-riTS-Rac1^{V12} toxicity
245 module to avoid false positives. Additionally, for E-Golic+, male founders showed
246 higher targeting efficiency, which helped us overcome the difficulties of knocking in
247 DBD in *Nkx6* and *Gal4* in *Gad1*.
248

249 obtained 37 offspring with *Nkx6:T2A:DBD* from a total of 175 male founders, but
250 recovered none from a total of 185 female founders. In the third case, we aimed to
251 insert Gal4 into *Gad1*, which encodes an enzyme characteristic of GABAergic
252 neurons, to make *Gad1:T2A:Gal4*. Expressing GAL4 continuously in all GABAergic
253 neurons could be harmful. In fact, an earlier study has reported challenges in
254 maintaining an analogous fly stock generated through recombinase-mediated
255 cassette exchange (Diao et al. 2015). Given the known challenges, we screened
256 through progeny from 300 male founders and recovered six offspring with
257 *Gad1:T2A:Gal4*. We validated the lines carrying *Gad1:T2A:Gal4* by genomic PCR, and
258 further corroborated their Gal4 expression patterns highlighting GABAergic
259 neurons in adult brains co-stained with anti-GABA antibody (Fig. 4). As expected, we
260 found that *Gad1:T2A:Gal4* labeled several prominent groups of GABAergic neurons
261 reported previously (Okada et al. 2009). We observed prominent labeling of R
262 neurons that innervate the ellipsoid body (Fig. 4A1), neurons dorsal, ventral, and
263 lateral to the antennal lobe neuropil (Fig. 4A2), neurons on the surface of Medulla
264 (Fig. 4A3), and neurons at the interface between medulla and lobula plate in the
265 posterior brain (Fig. 4A4). In addition to six correct gene-targeting lines carrying
266 *Gad1:T2A:Gal4*, we found three false positives with non-specific insertions. It is
267 unclear how a portion of circular DNA that contains the repressor became
268 integrated into the genome in these flies. However, the drastic suppression of non-
269 specific insertion in E-Golic⁺ is evident, indicating the importance of using extra-
270 chromosomal circular DNAs as templates for HDR.
271



272

273 **Figure. 4 The expression pattern of *Gad1:T2A:Gal4* in *Drosophila* central**
274 **nervous system.** (A) Composite confocal images of an adult fly brain with
275 *Gad1:T2A:Gal4* driving a neuronal membrane marker (10XUAS-mCD8-GFP, green).
276 The brain was counterstained with an anti-Bruchpilot protein antibody which
277 specifically label presynaptic active zones (blue). Partial projections of the boxed
278 regions in (A) were shown separately below together with anti-GABA staining
279 (Magenta). 1: The Ellipsoid Body (EB) region; 2: The Antennal Lobe (AL) region; 3:
280 The Medulla (Me) surface; 4: The interface between Medulla and Lobula Plate (LoP).
281 Lo: Lobula. Scale bar, 50um in all panels.

282 In sum, the enhanced Golic+ is particularly powerful in the male germline. The
283 lethality-based selections against false positives remain highly stringent. Moreover,
284 the efficiency of gene targeting is greatly enhanced such that we could readily
285 recuse all previously failed Golic+ experiments with E-Golic+.

286

287

288 **DISCUSSION**

289

290 Homology-dependent gene targeting allows designer genome editing, but suffers
291 from unpredictable success even with modern CRISPR/Cas9 technology. By tackling
292 previously failed gene-targeting trials, we show that the E-Golic+ reaches a 100%
293 success in gene targeting experiments. There are two levels of enhancement. First,
294 E-Golic+ offers absolute lethality selection to expedite the recovery of correct gene
295 targeting. Second, E-Golic+ achieves an exceptionally high efficiency of gene
296 targeting in male germline. E-Golic+ is probably the most sophisticated gene
297 targeting system to date. It amplifies the power of *Drosophila* genetics and
298 exemplifies how to access and modify the genomes of higher organisms.

299

300 Past studies have shown higher levels of gene targeting in female germline (Rong
301 and Golic 2000), but more efficient targeted mutagenesis in male germline (Bibikova
302 et al. 2002). Gene targeting depends on homologous recombination, while gene
303 disruption occurs through non-homologous repair. Such mechanistic distinctions
304 have promoted the idea that the lack of meiotic homologous recombination in

305 *Drosophila* male germline may underlie the previously published gender differences
306 in gene targeting versus gene disruption. However, our data suggest that male germ
307 cells are much more susceptible than female germ cells to Cas9-mediated genome
308 editing via HDR. These differences might result from repairs of double-strand DNA
309 breaks in germline stem cells versus germ cells. Interestingly, a recent paper
310 reported that CRISPR-induced DSBs can be repaired through recombination across
311 homologous chromosomes in germline stem cells (Brunner et al. 2019). We further
312 speculate that the homologous chromosomes in male germ cells might not be
313 intimately paired for recombination and thus individually more susceptible to
314 repairs by donor DNA. Nonetheless, we establish male germ cells as the top choice
315 for germline genome editing by E-Golic+ in *Drosophila*.

316

317 In our efforts to eliminate false positives, we confirmed that one could effectively
318 prevent off-target integration of the liberated donor DNA by keeping it in the intact
319 circular form. Once linearized, the donor DNA becomes prone to non-specific
320 insertion. Notably, the rate of non-specific insertion for linearized donor DNA varies
321 depending on the donor. Seemingly, there is an inverse correlation between the
322 non-specific insertion rate and the success rate of gene targeting. By contrast, it
323 appears that the off-target integration of circular donor DNAs remains persistently
324 suppressed regardless of actual gene-targeting efficiency. These phenomena
325 implicate differential fates for linear versus circular extra-chromosomal DNA,
326 further elucidation of which may help improve future gene targeting.

327

328 In sum, E-Golic+ in male germ cells has triumphed in previously failed gene-
329 targeting experiments with a 100% success rate. Impressively, almost 100% of
330 recovered candidates carried the desired genome modifications at the correct site.
331 Moreover, to achieve really intractable gene targeting, one can readily continue the
332 attempts by simple fly pushing. Given its unparalleled efficiency, specificity, and
333 scalability, enhanced Golic+ in male germ cells promises to enable further
334 sophisticated genome editing in *Drosophila* and beyond.

335

336

337 **MATERIAL AND METHODS**

338

339 **Fly strains**

340 Here are the fly strains used in this study: (1) *bamP(198)-Cas9:2A:FLP:2A:I-SceI* in
341 *su(Hw)attP8* and *attP2*; (2) *bamP(898)-Cas9:2A:FLP:2A:I-SceI* in *su(Hw)attP8* and
342 *attP2*; (3) *GMR3-LexA::GADd* in *attP40* and *VK00027*; (4) *nSyb-LexA::p65* in *attP16*
343 and *VK00027*; (5) *bamP(898)-Cas9:2A:FLP* in *su(Hw)attP8* and *attP2*; (6) *3X-riTS-*
344 *Rac1^{V12}(3xP3-RFP)* in *attP40* and *VK00027*.

345

346 **Molecular biology**

347 To create *vnd-T2A-KD*, *Nkx6-T2A-DBD*, and *Gad1-T2A-Gal4* knock-ins, 5' and 3'
348 homology arms of approximately 1.5 kb in length and right before or after the
349 *vnd*, *Nkx6*, and *Gad1* stop codons were amplified from genomic DNA and cloned
350 into pTL2. Homology arms were further mutated to avoid CRISPR cutting on the

351 donor. The following CRISPR target sites were chosen: vnd_gRNA#1:
352 GCATGGCCGTGCAGTAGACC; vnd_gRNA#2: GTTCCTCACCAGAACTGGAA;
353 Nkx6_gRNA#1: GAAATTAAGTCTTCAGAAGA; Nkx6_gRNA#2:
354 GCCATTTGGTGGCAGGATTC; Gad1_gRNA#1: GCTACCAGCCCGACGATCGC. T2A-KD
355 and T2A-DBD were introduced by cloning KD and DBD from pJFRC161-20XUAS-
356 IVS-KD::PEST (Nern et al. 2011) and pBPZpGAL4DBDUw (Pfeiffer et al. 2010). The
357 full *bam* promoter (-898) (Chen and McKearin 2003) was ordered from gBlocks, IDT
358 to create bamP(898)-Cas9:2A:FLP:2A:I-SceI. Afterwards, coding sequence of
359 Cas9:2A:FLP:2A:I-SceI was replaced by a PCR amplification of only the Cas9:2A:FLP
360 portion to generate bamP(898)-Cas9:2A:FLP.

361

362 **Fly genetics**

363 {vnd-T2A-KD, gRNA#1}, {vnd-T2A-KD, gRNA#2}, {Nkx6-T2A-DBD, gRNA#1},
364 {Nkx6-T2A-DBD, gRNA#2}, and {Gad1-T2A-Gal4} were all integrated in attP40 to
365 target *vnd* on the X chromosome, *Nkx6* and *Gad1* on the third chromosome.
366 Transgenic {*donor*, *gRNA*} donors were mated with flies carrying *bam898-CF* and
367 *3X-riTS-Rac1^{V12}(3xP3-RFP)* to create E-Golic+ founders. These founders were then
368 crossed to *nSyb-LexA* flies for lethality selection. Finally, for E-Golic+, only
369 surviving candidates labeled with 3xP3-RFP were subjected to chromosomal
370 mapping and genomic PCR confirmation.

371

372 **Immunostaining and fluorescence microscopy**

373 We dissected adult fly brains in ice-cold phosphate-buffered saline (PBS) and
374 immediately transferred them into 4% paraformaldehyde for fixation at room
375 temperature. After 30min fixation and three washes in PBS plus 0.5% Triton-X-100
376 (PBT), we added blocking solution (PBT with 4% Normal Goat Serum) and blocked
377 the brains for 1 hour. Next, we transferred the brains into blocking solution
378 containing primary antibodies and incubated at 4 °C overnight. After three 30-min
379 wash in PBT, we added secondary antibodies in blocking solution and incubated for
380 two days. Finally, after washing three additional times in PBT, we transferred the
381 brains into PBS and mounted in SlowFade Gold Reagent on charged slides
382 (Fisherbrand, 12-550-15).

383

384 Primary antibodies include: Chicken anti-GFP (1:1000; Life Technologies, A10262),
385 Rabbit anti-GABA (1:25; Millipore Sigma, A2052), and mouse anti-nc82 (1:40;
386 Developmental Studies Hydridoma Bank or DSHB). Secondary antibodies include:
387 Alexa-488-conjugated goat antibody to chicken (1:500; ThermoFisher Scientific, A-
388 11039), Cy3-conjugated goat antibody to Rabbit (1:200; Jackson ImmunoResearch,
389 #111-165-144), and Cy5-conjugated goat antibody to mouse (1: 200; Jackson
390 ImmunoResearch, #115-605-146).

391

392 We acquired image stacks of whole-mount fly brains using a Zeiss LSM 710 confocal
393 microscope. The images were taken at 1um intervals at 1024x1024 pixel resolution
394 using a 40X C-Apochromat water objective (NA=1.2). The images were further
395 processed with Fiji and Adobe Photoshop.

396

397

398 **Acknowledgements**

399 We thank Dr. Phillip Port and Dr. Kate Koles for helpful discussion. We thank Dr.

400 Rosa Linda Miyares for critical editing of the manuscript. We thank Janelia Fly

401 Core for technical support. We thank Crystal Di Pietro and Kathryn Miller for

402 administrative support. This work was supported by Howard Hughes Medical

403 Institute.

404

405

406 **Competing interests**

407 The authors declare no competing interests.

408

409 **Author contributions**

410 H.-M.C. and T.L. conceived the project. H.-M.C. performed the experiments. X.Y. and

411 C.-C.C. generated E-Golic+ constructs. Q.R. analyzed the Gad1-T2A-Gal4 expression

412 patterns. L.-Y.L. assisted in E-Golic+ screening. H.-M.C. and T.L. wrote the

413 manuscript. T.L. supervised the project.

414

415 References

416

- 417 Allen F, Crepaldi L, Alsinet C, Strong AJ, Kleshchevnikov V, De Angeli P, Palenikova P,
418 Khodak A, Kiselev V, Kosicki M et al. 2018. Predicting the mutations
419 generated by repair of Cas9-induced double-strand breaks. *Nat Biotechnol.*
420 Beumer KJ, Trautman JK, Bozas A, Liu J-L, Rutter J, Gall JG, Carroll D. 2008. Efficient
421 gene targeting in *Drosophila* by direct embryo injection with zinc-finger
422 nucleases. *Proceedings of the National Academy of Sciences* **105**: 19821-
423 19826.
- 424 Bibikova M, Golic M, Golic KG, Carroll D. 2002. Targeted chromosomal cleavage and
425 mutagenesis in *Drosophila* using zinc-finger nucleases. *Genetics* **161**: 1169-
426 1175.
- 427 Brunner E, Yagi R, Debrunner M, Beck-Schneider D, Burger A, Escher E, Mosimann C,
428 Hausmann G, Basler K. 2019. CRISPR-induced double-strand breaks trigger
429 recombination between homologous chromosome arms. *Life science alliance*
430 **2**.
- 431 Chen D, McKearin DM. 2003. A discrete transcriptional silencer in the *bam* gene
432 determines asymmetric division of the *Drosophila* germline stem cell.
433 *Development* **130**: 1159-1170.
- 434 Chen HM, Huang Y, Pfeiffer BD, Yao X, Lee T. 2015. An enhanced gene targeting
435 toolkit for *Drosophila*: Golic+. *Genetics* **199**: 683-694.
- 436 Diao F, Ironfield H, Luan H, Diao F, Shropshire WC, Ewer J, Marr E, Potter CJ,
437 Landgraf M, White BH. 2015. Plug-and-play genetic access to *drosophila* cell
438 types using exchangeable exon cassettes. *Cell reports* **10**: 1410-1421.
- 439 Fuller MT, Spradling AC. 2007. Male and female *Drosophila* germline stem cells: two
440 versions of immortality. *Science* **316**: 402-404.
- 441 Horlbeck MA, Witkowski LB, Guglielmi B, Replogle JM, Gilbert LA, Villalta JE,
442 Torigoe SE, Tjian R, Weissman JS. 2016. Nucleosomes impede Cas9 access to
443 DNA in vivo and in vitro. *eLife* **5**.
- 444 Hwang WY, Fu Y, Reyon D, Maeder ML, Tsai SQ, Sander JD, Peterson RT, Yeh JJ, Joung
445 JK. 2013. Efficient genome editing in zebrafish using a CRISPR-Cas system.
446 *Nature biotechnology* **31**: 227-229.
- 447 Isaac RS, Jiang F, Doudna JA, Lim WA, Narlikar GJ, Almeida R. 2016. Nucleosome
448 breathing and remodeling constrain CRISPR-Cas9 function. *eLife* **5**.
- 449 Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna JA, Charpentier E. 2012. A
450 programmable dual-RNA-guided DNA endonuclease in adaptive bacterial
451 immunity. *Science* **337**: 816-821.
- 452 Komor AC, Badran AH, Liu DR. 2017. CRISPR-Based Technologies for the
453 Manipulation of Eukaryotic Genomes. *Cell* **169**: 559.
- 454 Lehmann R. 2012. Germline stem cells: origin and destiny. *Cell stem cell* **10**: 729-
455 739.

- 456 Lieber MR. 2010. The mechanism of double-strand DNA break repair by the
457 nonhomologous DNA end-joining pathway. *Annual review of biochemistry* **79**:
458 181-211.
- 459 Nern A, Pfeiffer BD, Svoboda K, Rubin GM. 2011. Multiple new site-specific
460 recombinases for use in manipulating animal genomes. *Proceedings of the*
461 *National Academy of Sciences of the United States of America* **108**: 14198-
462 14203.
- 463 Okada R, Awasaki T, Ito K. 2009. Gamma-aminobutyric acid (GABA)-mediated
464 neural connections in the *Drosophila* antennal lobe. *The Journal of*
465 *comparative neurology* **514**: 74-91.
- 466 Pfeiffer BD, Ngo T-TB, Hibbard KL, Murphy C, Jenett A, Truman JW, Rubin GM. 2010.
467 Refinement of tools for targeted gene expression in *Drosophila*. *Genetics* **186**:
468 735-755.
- 469 Rong YS, Golic KG. 2000. Gene targeting by homologous recombination in
470 *Drosophila*. *Science* **288**: 2013-2018.
- 471 San Filippo J, Sung P, Klein H. 2008. Mechanism of eukaryotic homologous
472 recombination. *Annual review of biochemistry* **77**: 229-257.
473

474 **Figure Legends**

475

476 **Figure 1. Improvements of E-Golic+ to remove two types of false positives,**
477 **escapers and non-specific insertions.** (A) In Golic+, {donor} was designed with
478 two built-in toxicity modules and integrated in pre-characterized *attP* sites for
479 efficient donor DNA release. We detected two false positive scenarios that produced
480 progeny evading lethality selection. For escapers, they originated from failures in
481 the reconstitution of a toxic module at the {donor} residual site, due to either
482 imprecise flip-out or destructive premature I-SceI cutting. Therefore, they eclosed
483 without ever being challenged by the lethality selection. For non-specific insertions,
484 they retained the rCD2i suppressor and primarily relocated into the same
485 chromosome. Yet they lost the ancillary non-repressible toxic module over this
486 process, and survived the lethality selection without going through HDR. (B) We
487 created 3xP3-RFP labeled *3XLexAop2-riTS-Rac1^{V12}* transgenic lines, and
488 purposefully only collected surviving candidates marked with red fluorescent eyes.
489 Hence, we effectively screened for candidates carrying the rCD2i suppressor, and
490 avoid escapers completely. (C) Using *bamP(898)-Cas9:T2A:FLP*, we induced HDR in
491 germ cells with CRISPR and circular donor DNA, hence directly relieved ourselves
492 from the occurrence of non-specific insertions originating from linear donor DNA.

493

494 **Figure 2. Targeting schemes for a second or an X chromosome gene.** Like
495 Golic+, E-Golic+ involves two crosses and three steps. In the first cross, we create
496 founders that have active CRISPR reactions with circular donor for HDR in their

497 germ cells. Then, founders are mated with *nSyb-LexA* so that each progeny will
498 experience lethality selection, and most, if not all, of the 3xP3-RFP marked surviving
499 candidates inherit gene targeting events marked with rCD2i suppressor.

500

501 **Figure 3. E-Golic+ effectively eliminates the occurrence of false positives.** To
502 evaluate the new transgenes introduced in E-Golic+, we performed gene targeting
503 with five different donors using either Golic+ or E-Golic+. Occurrence of three
504 different types of gene targeting candidates (correct targeting, non-specific
505 insertion, and escapers) out of every 100 female founders are numbers interpolated
506 or extrapolated from data in Table 2.

507

508 **Figure. 4 The expression pattern of *Gad1:T2A:Gal4* in *Drosophila* central**
509 **nervous system.** (A) Composite confocal images of an adult fly brain with
510 *Gad1:T2A:Gal4* driving a neuronal membrane marker (10XUAS-mCD8-GFP, green).
511 The brain was counterstained with an anti-Bruchpilot protein antibody which
512 specifically label presynaptic active zones (blue). Partial projections of the boxed
513 regions in (A) were shown separately below together with anti-GABA staining
514 (Magenta). 1: The Ellipsoid Body (EB) region; 2: The Antennal Lobe (AL) region; 3:
515 The Medulla (Me) surface; 4: The interface between Medulla and Lobula Plate (LoP).
516 Lo: Lobula. Scale bar, 50um in all panels.

517

518 **Tables**

519

520 **Table 1. List of transgenic lines required for implementing Enhanced Golic+**

521

Full Name	Abbreviation	Integration Site(s)	Notes
donor DNA plus gRNA in pTL2	{donor, gRNA}	attP40, VK00027	Needs to be created for each gene-targeting experiment.
GMR3-LexA::GADd	GMR3-LexA	attP40, VK00027	Cross with {donor, gRNA} injected adults to create rough eyes for {donor} transformant screening.
bamP(898)-Cas9-P2A-FLP	bam898-CF	su(Hw)attP8, attP2	Expresses Cas9 and FLP under bamP control to introduce DSB at the target locus and release donor DNA in every germ cell.
3XLexAop2-rCD2miRNATS#6-Rac1 ^{V12} (3xP3-RFP)	3X-riTS-Rac1 ^{V12}	attP40, VK00027	Together with {donor, gRNA}*, provides a homozygous suppressible “Toxic” background.
Residual {donor, gRNA}	{donor, gRNA}*		After donor release, it will reconstitute as a suppressible toxic module, 5X-FRT-riTS-Rac1 ^{V12} .
nSyb-LexA::p65	nSyb-LexA	attP16, VK00027	Induce larval/pupal lethality selection

522

523 **Table 2. Comparison of Golic+ and Enhanced Golic+**

	# of Founders	Correct Targeting	Non-Specific Insertion	Escapers
Golic+	Female			
{ <i>vnd-T2A-KD, gRNA#1</i> }	100	0	17	47
{ <i>vnd-T2A-KD, gRNA#2</i> }	100	0	28	49
E-Golic+	Female			
{ <i>vnd-T2A-KD, gRNA#1</i> }	150	4	0	0
{ <i>vnd-T2A-KD, gRNA#2</i> }	150	13	0	0
E-Golic+	Male			
{ <i>vnd-T2A-KD, gRNA#1</i> }	100	49	0	0
{ <i>vnd-T2A-KD, gRNA#2</i> }	100	24	0	0
Golic+	Female			
{ <i>Nkx6-T2A-DBD, gRNA#1</i> }	50	0	29	39
{ <i>Nkx6-T2A-DBD, gRNA#2</i> }	50	0	24	23
E-Golic+	Female			
{ <i>Nkx6-T2A-DBD, gRNA#1</i> }	65	0	0	0
{ <i>Nkx6-T2A-DBD, gRNA#2</i> }	120	0	0	0
E-Golic+	Male			
{ <i>Nkx6-T2A-DBD, gRNA#1</i> }	75	16	0	0
{ <i>Nkx6-T2A-DBD, gRNA#2</i> }	100	21	0	0
Golic+	Female			
{ <i>Gad1-T2A-Gal4, gRNA#1</i> }	350	0	12	56
E-Golic+	Female			
{ <i>Gad1-T2A-Gal4, gRNA#1</i> }	100	0	0	0
E-Golic+	Male			
{ <i>Gad1-T2A-Gal4, gRNA#1</i> }	300	6	3	0

524 To examine the improvements made on E-Golic+, both Golic+ and E-Golic+ were
525 applied to create *vnd-T2A-KD*, *Nkx6-T2A-DBD*, and *Gad1-T2A-Gal4* knock-ins. In the
526 last *Gad1-T2A-Gal4* knock-in case, we only construct one {donor, gRNA} for
527 targeting. Female founders were used in both Golic+ and E-Golic+ to reveal the
528 benefits of adopting circular donor plus a 3xP3-RFP marked 3X-riTS-Rac1^{V12} toxicity
529 module to avoid false positives. Additionally, for E-Golic+, male founders showed
530 higher targeting efficiency, which helped us overcome the difficulties of knocking in
531 DBD in *Nkx6* and Gal4 in *Gad1*.

532

533 **Supplemental Table. Golic+, comparing *bam198-CFI* and *bam898-CFI* with**
534 ***{msh-T2A-Gal4 KI, gRNA}***
535

	# of Female Founders	Correct Targeting	Non-Specific Insertion	Escapers
<i>bam198-CFI</i>	95	47	8	15
<i>bam898-CFI</i>	30	37	53	5

536 Using a common donor *{msh-T2A-Gal4 KI, gRNA}*, we compare the performance of
537 *bam198-CFI* and *bam898-CFI* in terms of the production of correct targeting, non-
538 specific insertion, and escaper candidates.